BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Wednesday, May 27, 2026
Home » Money raised by biotech: 2019 vs. 2018

Money raised by biotech: 2019 vs. 2018

May 28, 2019

Article reprints

To read more on related topics, click on one of the words below.

BioWorld

    • Related Articles

      Money raised by biotech: 2019 vs. 2018

      Money raised by biotech: 2019 vs. 2018

      Money raised by biotech: 2019 vs. 2018

    Popular Stories

    • Today's news in brief

      BioWorld
      BioWorld briefs for May 26, 2026.

    • News in brief

      BioWorld Asia
      BioWorld Asia briefs for May 26, 2026
    • Microscopy of a cross-section of mouse skin containing melanoma tumors

      Researchers identify innate immune barrier against melanoma

      BioWorld
      Australian researchers have identified a previously overlooked population of immune cells in the skin that physically restrain melanoma growth by engulfing live...

    • Cavalon Therapeutics and Northwestern patent new Cav1.3 blockers

      BioWorld Science
      Cavalon Therapeutics Inc. and Northwestern University have disclosed new voltage-gated calcium channel Cav1.3 blockers potentially useful for the treatment of...
    • Green and red bispecific antibodies

      Biotle’s FcRn inhibitor BTL-203 cleared for clinic in China

      BioWorld Science
      Biotle has received a clinical trial notice from China’s National Medical Products Administration (NMPA) for its IND application for BTL-203, the company’s...
    • BioWorld
      • Today's news
      • Analysis and data insight
      • Clinical
      • Data Snapshots
      • Deals and M&A
      • Financings
      • Medical technology
      • Newco news
      • Opinion
      • Regulatory
    • BioWorld Science
      • Today's news
      • Biomarkers
      • Cancer
      • Conferences
      • Endocrine/metabolic
      • Immune
      • Infection
      • Neurology/psychiatric
      • NME Digest
      • Patents
    • BioWorld Asia
      • Today's news
      • Analysis and data insight
      • Australia
      • China
      • Clinical
      • Deals and M&A
      • Financings
      • Newco news
      • Regulatory
      • Science
    • More
      • About
      • Advertise with BioWorld
      • Archives
      • Article reprints and permissions
      • Contact us
      • Cookie policy
      • Copyright notice
      • Data methodology
      • Infographics: Dynamic digital data analysis
      • Index insights
      • Podcasts
      • Privacy policy
      • Share your news with BioWorld
      • Staff
      • Terms of use
      • Topic alerts
    Follow Us

    Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing